Compare Crispr Therapeutics AG (CRSP) vs Royalty Pharma plc Class A Ordinary Shares (RPRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? Crispr Therapeutics AG trades at $53.39 (market cap $4.88B), while Royalty Pharma plc Class A Ordinary Shares trades at $56.93 (market cap $25.27B). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 5.2× Crispr Therapeutics AG's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Royalty Pharma plc Class A Ordinary Shares for 1 Days on average.
| CRSP | RPRX | |
|---|---|---|
Market Cap | $4.88B | $25.27B |
Volume | 2,861,747 | 3,671,183 |
Sector | Health | Health |
52-Week High | $74.92 | $63.96 |
52-Week Low | $44.34 | $35.44 |
Typical Hold Time | 77 Days | 1 Days |
Enterprise Value | $3.30B | $32.50B |
Dividend Yield | — | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.39, up 1.99% on the day, but remains in a bearish technical trend. The company shows no revenue in 2025, with significant losses (net income margin -4,101.26%) and negative cash flow from operations. However, analyst sentiment is positive with a 57.9% buy rating and a $67.83 consensus price target, citing upcoming clinical data catalysts for its gene-editing therapies like CASGEVY and zugo-cel.
The outlook hinges on successful clinical execution and commercialization of its pipeline. Near-term catalysts include data readouts in autoimmune diseases, but high cash burn, intense competition, and regulatory risks pose substantial challenges. The stock offers high-risk, high-reward potential for investors betting on gene-editing breakthroughs.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →
